Pivmecillinam (Pivya) for Uncomplicated UTI
The Medical Letter on Drugs and Therapeutics · 13.04.2026 · 68 (1752) · 57-59
DOI: 10.58347/tml.2026.1752a ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 13.04.2026.
Abstract (Originalsprache)
The FDA has approved pivmecillinam (Pivya – Utility Therapeutics), an oral penicillin-class antibacterial drug, for treatment of uncomplicated urinary tract infections (uUTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis, or Staphylococcus saprophyticus in adult females. Pivmecillinam was approved by the FDA in 2024 but only recently became available in the US. It has been used in Europe for over 40 years.
Schlagwörter
Stichwörter der Autor:innen
Zitieren
APA
(2026). Pivmecillinam (Pivya) for Uncomplicated UTI. The Medical Letter on Drugs and Therapeutics, 68(1752), 57-59. https://doi.org/10.58347/tml.2026.1752a
Vancouver
Pivmecillinam (Pivya) for Uncomplicated UTI. The Medical Letter on Drugs and Therapeutics. 2026;68(1752):57-59. doi:10.58347/tml.2026.1752a
BibTeX
@article{euvimed2026,
title = {Pivmecillinam (Pivya) for Uncomplicated UTI},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2026},
volume = {68},
number = {1752},
pages = {57--59},
doi = {10.58347/tml.2026.1752a}
}
EUVIMED